Mevastatin
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Mevastatin | |||||||||||||||||||||
other names |
|
|||||||||||||||||||||
Molecular formula | C 23 H 34 O 5 | |||||||||||||||||||||
Brief description |
colorless crystals |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
Drug class | ||||||||||||||||||||||
Mechanism of action | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 390.51 g mol −1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point |
152 ° C |
|||||||||||||||||||||
solubility | ||||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Mevastatin , also called compactin, is an active ingredient from the group of statins used to treat disorders of lipid metabolism . It was the first HMG-CoA reductase - inhibitor in the 1970s from Penicillium citrinum was isolated.
Mevastatin is not used in the therapy of lipid metabolism disorders because it has many side effects. However, it is used as the starting compound for the production of other statins such as pravastatin .
Individual evidence
- ↑ a b c Entry on Compactin. In: Römpp Online . Georg Thieme Verlag, accessed on June 21, 2014.
- ↑ a b Registration dossier for (1S, 7S, 8S, 8aR) -8- {2 - [(2R, 4R) -4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl] ethyl} -7-methyl- 1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S) -2-methylbutanoate ( GHS section ) from the European Chemicals Agency (ECHA), accessed on July 7, 2020.
- ↑ Entry on mevastatin in the ChemIDplus database of the United States National Library of Medicine (NLM), accessed on July 7, 2020.